Kidney Transplantation Clinical Trial
Official title:
Effects of Stochastic Whole-body Vibration Physiotherapy-WBV (Stochastic Resonance Physiotherapy-SRT) on Muscle Strength in Patients After Kidney Transplantation: a Pilot Study
Kidney recipients loose significant amounts of muscle mass and skeleton minerals in the early
post-transplantation period and suffer from increasing abnormalities of neuromuscular
functions.
Stochastic whole body vibration (WBV) therapy is a relatively new form of movement
physiotherapy that is used for strength training. Various clinical studies have shown that in
addition to muscle function, WBV also improved body balance and bone mineral density. To
study the impact of stochastic WBV physiotherapy on musculoskeletal parameters after renal
transplantation, kidney transplant recipients will be enrolled and undergo WBV. The
investigators hypothesize that WBV physiotherapy improves both maximum muscle strength and
muscular performance
Background
The increasing incidence of muscular wasting, bone disease, falls and related fractures are
the price for excellent survival rates in transplanted patients. Kidney recipients loose
significant amounts of muscle mass and skeleton minerals in the early post-transplantation
period and suffer from increasing abnormalities of neuromuscular functions.
Recently, stochastic whole-body vibration (WBV) has received much attention as a potential
muscle-anabolic and anti-osteoporotic intervention. It is suggested that the randomized
low-frequency signals produced during such training can activate otherwise high threshold
afferent and efferent motor-neurons and thus may result in a considerable neuromuscular
activation. Additionally, there data supporting peripherally-induced central biochemical
activation, that meaning the production of CNS modulators due to application of mechanical
exercise such as stochastic WBV. The result is a rapid (within minutes), transient force
increase. Due to the high number of stimuli-repetitions, it is possible to increase muscle
strength using shorter training times (<5 min) than with conventional physiotherapeutic
methods (> 30 min). Several experimental and clinical studies have shown that in addition to
muscle function, WBV also improved body balance and bone mineral density.
Moreover, a population of renal transplant recipients has not yet been studied elsewhere.
WBV is a very appealing approach, foremost in subjects with limited physical activity; it
represents a potentially simple and efficient training method for skeletal muscle and better
functional performance, thus preventing falls and consequently fractures.
Objective
Primary:
- To determine the effect of post-transplantation stochastic WBV therapy on preservation of
functional muscle strength.
Secondary:
To assess a) the efficacy of post-transplantation stochastic WBV on body balance b) the
efficacy of post-transplantation stochastic WBV on preservation of lean muscle mass
determined by Magnetic Resonance Spectroscopy (MRS) c) the changes in bone turnover markers
in renal transplant recipients under stochastic WBV therapy d) the short-term safety of
stochastic WBV therapy in renal transplant recipients.
Methods
Prospective, randomized, double-blinded, placebo-controlled setting.
Recruited individuals will be randomized in Group 1 (intervention) and in Group 2 (placebo).
All participants will be evaluated monthly for occurrence of falls and fractures, and
treatment-associated side effects. Testing will be performed upon study entry and at 3 and 6
months according to the following schedule:
Visit 1 (Baseline):
- Muscle strength measurement
- Neuromuscular tests (SPPBT)
- Magnetic resonance spectroscopy (MRS)
- Turnover Markers (blood) Visits 2 and 3 (after 3 and 6 months respectively): Identical
to visit 1
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT02723591 -
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT05945511 -
Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
|
||
Completed |
NCT02234349 -
Bile Acids and Incretins in Pancreas Kidney Transplant Patients
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT05934383 -
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
|
N/A | |
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Not yet recruiting |
NCT04540640 -
Oxygenated Machine Preservation in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Completed |
NCT02560558 -
Bela 8 Week Dosing
|
Phase 4 | |
Terminated |
NCT02417870 -
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02154815 -
Pre-emptive Kidney Transplantation Quality of Life
|
N/A | |
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Enrolling by invitation |
NCT01905514 -
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
|
N/A | |
Completed |
NCT02147210 -
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
|
N/A | |
Recruiting |
NCT01699360 -
The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
|
Phase 4 | |
Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 |